Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
Companies
» Company Monitoring Page for Roche
Company Monitoring Page for Roche
latest headlines for company on cafepharma
Roche's Avastin Successful In Late-Stage Ovarian Cancer Trials
FOX Business
Tue, 02/8/11 - 11:55 am
Tags:
ovarian cancer
,
Avastin
,
Roche
Roche chief accentuates Avastin's positives
Fierce Pharma
Mon, 02/7/11 - 11:30 am
Tags:
Roche
,
Avastin
,
Severin Schwan
,
Pharma CEOs
Value Pharma Stocks in Overpriced Market
Seeking Alpha
Sat, 02/5/11 - 10:59 am
Tags:
Abbott Laboratories
,
AstraZeneca
,
Bristol-Myers Squibb
,
Eli Lilly
,
GSK
,
JNJ
,
Merck
,
Novartis
,
Pfizer
,
Roche
,
Sanofi
Roche Reduces Avastin Forecast as Revenue Declines
Bloomberg
Wed, 02/2/11 - 09:03 am
Tags:
Roche
,
Avastin
,
earnings
Roche Said to Return Diabetes Drug Rights to Ipsen
Bloomberg
Tue, 02/1/11 - 08:25 am
Tags:
Ipsen
,
Roche
,
diabetes
,
taspoglutide
Roche’s Tarceva Extends Lives, Study Stopped Early
Bloomberg
Fri, 01/28/11 - 09:41 am
Tags:
Astellas
,
Tarceva
,
lung cancer
,
Roche
Roche Scores Big With Plexxikon and Immunogen Deals
Seeking Alpha
Tue, 01/25/11 - 09:30 am
Tags:
Roche
,
Immunogen
,
Plexxikon
,
personalized medicine
Major Drugmaker Sales Growth to Slow to 1.3%, Datamonitor Says
Bloomberg
Fri, 01/21/11 - 08:00 am
Tags:
Bayer
,
Novartis
,
Roche
,
GSK
,
drug sales
Why Big Pharma Is the New Big Biotech
Seeking Alpha
Fri, 01/21/11 - 07:57 am
Tags:
Big Pharma
,
Amgen
,
Celgene
,
Gilead Sciences
,
Roche
Genentech cites chemo comparisons in Avastin appeal
Fierce Pharma
Wed, 01/19/11 - 11:16 am
Tags:
Avastin
,
Roche
,
Genentech
,
FDA
,
breast cancer
Biosimilars: Empty Threats?
InVivo
Tue, 01/18/11 - 11:58 am
Tags:
biosimilars
,
Novartis
,
Sandoz
,
Roche
,
Rituxan
The FDA approvals of 2010
Fierce Biotech
Wed, 01/12/11 - 07:24 pm
Tags:
Watson Pharmaceuticals
,
Theratechnologies
,
Shire
,
Savient
,
Sanofi
,
Roche
,
Orphan Europe
,
Novo Nordisk
,
Novartis
,
Merz
,
JNJ
,
HRA Pharma
,
Genzyme
,
Forest Labs
,
FDA
,
Eisai
,
Dainippon Sumitomo
,
Chemiche Fabrik Kresussler
,
Boehringer Ingelheim
,
Bayer
,
Auxilium
,
Amgen
,
Allergan
,
Acorda Therapeutics
Roche, Avastin And An Influential Cancer Doc Panel
Pharmalot
Tue, 01/11/11 - 02:41 pm
Tags:
Avastin
,
Roche
,
Genentech
,
FDA
,
breast cancer
Medicare contractor won't stop paying for Avastin
Fierce Pharma
Mon, 01/10/11 - 12:40 pm
Tags:
Avastin
,
Medicare
,
Roche
,
Genentech
,
breast cancer
Novartis plans trial of equivalent to Roche drug
Marketwatch
Mon, 01/10/11 - 12:16 pm
Tags:
Roche
,
Novartis
,
biosimilars
,
Rituxan
,
Sandoz
,
rheumatoid arthritis
,
rituximab
Avastin Decision Not Based On Cost: FDA Official
Pharmalot
Fri, 01/7/11 - 09:59 am
Tags:
Avastin
,
FDA
,
breast cancer
,
Roche
Spectrum Pharma Jumps in With the Big Dogs
Motley Fool
Thu, 01/6/11 - 07:40 am
Tags:
Spectrum Pharmaceuticals
,
Roche
,
biosimilars
,
Biogen Idec
,
Rituxan
Roche Wins Broader U.S. Approval for Actemra Arthritis Drug
Bloomberg
Thu, 01/6/11 - 07:39 am
Tags:
Actemra
,
Roche
,
arthritis
Avastin raises heart failure risk in breast cancer
Reuters
Wed, 01/5/11 - 11:43 am
Tags:
Roche
,
Avastin
,
heart failure
,
breast cancer
NICE may bless off-label Avastin use in eyes
Fierce Pharma
Tue, 01/4/11 - 12:11 pm
Tags:
NICE
,
Avastin
,
off-label
,
Roche
Pages
« first
‹ previous
…
98
99
100
101
102
103
104
105
106
…
next ›
last »
last 30 twitter posts
current feelings about your job
job rating
*
1 - I hate my job
2
3
4
5
6
7 - I love my job
Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
please tell us why
*
your industry
*
your job title (optional)
your company
*
published
N/A
published
not published
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
An earthquake would most likely shake a: idea, building, breeze
*
Fill in the blank.